Dr. Jana Horakova

Dr. Jana Horakova is a consultant rheumatologist at University Hospital Bratislava with 15 years of specialist experience, specialising in inflammatory arthritis, autoimmune disease, and osteoporosis. She holds MD and PhD qualifications, reflecting her dual clinical and research role in rheumatology. University Hospital Bratislava provides a comprehensive rheumatology service aligned with European standards, offering biologic and targeted synthetic DMARD therapy for inflammatory joint and autoimmune diseases. Dr. Horakova's expertise in biologic therapy — including TNF inhibitors, IL-6 inhibitors, JAK inhibitors, and B-cell depleting agents — places her at the forefront of modern rheumatological practice in Central Europe.

Dr. Horakova completed her MD at Comenius University Faculty of Medicine in Bratislava and undertook rheumatology residency and specialist training at University Hospital Bratislava. She earned her PhD, contributing peer-reviewed research to rheumatology, including work on biologic therapy outcomes in inflammatory arthritis. Her rheumatology training encompassed diagnosis and management of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, Sjögren's syndrome, and osteoporosis. She has completed training in musculoskeletal ultrasound for joint assessment and guided injection therapy. She participates in EULAR (European League Against Rheumatism) Congress and Slovak rheumatology CME programmes.

Dr. Horakova manages the full spectrum of inflammatory and autoimmune rheumatic diseases. Her inflammatory arthritis expertise covers rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, applying treat-to-target strategies with conventional DMARDs (methotrexate, leflunomide, sulfasalazine) and biologic/targeted synthetic DMARDs (TNF inhibitors, IL-6 inhibitors, JAK inhibitors, IL-17 inhibitors, IL-12/23 inhibitors). Her autoimmune disease practice covers systemic lupus erythematosus, primary Sjögren's syndrome, myositis, and systemic sclerosis, using immunomodulatory and immunosuppressive regimens. Her osteoporosis practice encompasses DXA assessment, fracture risk stratification using FRAX, and initiation of antiresorptive or anabolic therapy.

University Hospital Bratislava's rheumatology department serves patients from Slovakia and the broader Central European region. International patients seeking specialist rheumatology opinions, biologic therapy access, or second opinions on inflammatory arthritis treatment plans can access Dr. Horakova's services. Slovakia's EU membership and alignment with EULAR guidelines ensure treatment to European standards. Dr. Horakova consults in Slovak, Czech, and English. Bratislava's proximity to Vienna provides easy international transport access. The hospital can provide English-language rheumatology reports and pre-visit teleconsultation for international patients.

Dr. Horakova has been recognised by the Slovak Rheumatological Society and the University Hospital Bratislava for her contributions to inflammatory arthritis and biologic therapy. Her PhD from Comenius University reflects peer-evaluated research contribution to rheumatology. She has been invited to present at EULAR Congress and regional Central European rheumatology meetings. She has contributed to Slovak national rheumatology guideline development and has been commended for advancing biologic therapy access for patients with severe inflammatory arthritis in Slovakia.